184 related articles for article (PubMed ID: 32415711)
1. Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation.
Lavacca A; Presta R; Gai C; Mella A; Gallo E; Camussi G; Abbasciano I; Barreca A; Caorsi C; Fop F; Messina M; Rossetti M; Biancone L
Clin Transplant; 2020 Aug; 34(8):e13908. PubMed ID: 32415711
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
[TBL] [Abstract][Full Text] [Related]
3. Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection.
Shin BH; Everly MJ; Zhang H; Choi J; Vo A; Zhang X; Huang E; Jordan SC; Toyoda M
Transplantation; 2020 Apr; 104(4):856-863. PubMed ID: 31385933
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review.
Cabezas L; Jouve T; Malvezzi P; Janbon B; Giovannini D; Rostaing L; Noble J
Front Immunol; 2022; 13():839380. PubMed ID: 35493469
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab in the treatment of active chronic humoral rejection resistant to standard therapy.
Chamoun B; Sánchez-Sancho P; Torres IB; Gabaldon A; Perelló M; Sellarés J; Moreso F; Serón D
Nefrologia (Engl Ed); 2022; 42(5):578-584. PubMed ID: 36717307
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study.
Bachelet T; Nodimar C; Taupin JL; Lepreux S; Moreau K; Morel D; Guidicelli G; Couzi L; Merville P
Clin Transplant; 2015 May; 29(5):439-46. PubMed ID: 25739833
[TBL] [Abstract][Full Text] [Related]
8. Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab.
Mulley WR; Huang LL; Ramessur Chandran S; Longano A; Amos LAR; Polkinghorne KR; Nikolic-Paterson DJ; Kanellis J
Clin Transplant; 2017 Sep; 31(9):. PubMed ID: 28640458
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation.
Kim MG; Kim YJ; Kwon HY; Park HC; Koo TY; Jeong JC; Jeon HJ; Han M; Ahn C; Yang J
Nephrology (Carlton); 2013 Dec; 18(12):820-6. PubMed ID: 24033843
[TBL] [Abstract][Full Text] [Related]
10. Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection.
Piñeiro GJ; De Sousa-Amorim E; Solé M; Ríos J; Lozano M; Cofán F; Ventura-Aguiar P; Cucchiari D; Revuelta I; Cid J; Palou E; Campistol JM; Oppenheimer F; Rovira J; Diekmann F
BMC Nephrol; 2018 Oct; 19(1):261. PubMed ID: 30309322
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients.
Khairallah P; Robbins-Juarez S; Patel S; Shah V; Toma K; Fernandez H; Dube GK; King K; Mohan S; Husain SA; Morris H; Crew RJ
Clin Transplant; 2023 Jan; 37(1):e14853. PubMed ID: 36398915
[TBL] [Abstract][Full Text] [Related]
12. Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients.
Pearl M; Weng PL; Chen L; Dokras A; Pizzo H; Garrison J; Butler C; Zhang J; Reed EF; Kim IK; Choi J; Haas M; Zhang X; Vo A; Chambers ET; Ettenger R; Jordan S; Puliyanda D
Clin Transplant; 2022 Aug; 36(8):e14734. PubMed ID: 35657013
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection.
Hong YA; Kim HG; Choi SR; Sun IO; Park HS; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
Transplant Proc; 2012 Jan; 44(1):182-4. PubMed ID: 22310610
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological analyses of transplant glomerulopathy cases.
Shimizu T; Ishida H; Toki D; Nozaki T; Omoto K; Tanabe K; Honda K; Koike J
Nephrology (Carlton); 2014 Jun; 19 Suppl 3():21-6. PubMed ID: 24842817
[TBL] [Abstract][Full Text] [Related]
15. A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients.
Vo AA; Choi J; Kim I; Louie S; Cisneros K; Kahwaji J; Toyoda M; Ge S; Haas M; Puliyanda D; Reinsmoen N; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Nov; 99(11):2356-63. PubMed ID: 26018350
[TBL] [Abstract][Full Text] [Related]
16. Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation?
Massat M; Congy-Jolivet N; Hebral AL; Esposito L; Marion O; Delas A; Colombat M; Faguer S; Kamar N; Del Bello A;
Am J Transplant; 2021 Apr; 21(4):1641-1649. PubMed ID: 33141487
[TBL] [Abstract][Full Text] [Related]
17. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Bortezomib as an Adjunctive Therapy for Refractory Chronic Active Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience.
Larpparisuth N; Skulratanasak P; Premasathian N; Vongwiwatana A
Transplant Proc; 2019 Dec; 51(10):3293-3296. PubMed ID: 31732214
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection.
Macklin PS; Morris PJ; Knight SR
Transplant Rev (Orlando); 2017 Apr; 31(2):87-95. PubMed ID: 28187998
[TBL] [Abstract][Full Text] [Related]
20. Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results.
Mella A; Gallo E; Messina M; Caorsi C; Amoroso A; Gontero P; Verri A; Maletta F; Barreca A; Fop F; Biancone L
World J Transplant; 2018 Sep; 8(5):178-187. PubMed ID: 30211026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
